Abstract
Bipolar disorder (BD) is a neuropsychiatric mood disorder manifested by recurrent episodes of mania and depression. More than half of BD patients are non-responsive to lithium, the first-line treatment drug, complicating BD clinical management. Given its unknown etiology, it is pertinent to understand the genetic signatures that lead to variability in lithium response. We discovered a set of differentially expressed genes (DEGs) from the lymphoblastoid cell lines (LCLs) of 10 controls and 19 BD patients belonging mainly to the immunoglobulin gene family that can be used as potential biomarkers to diagnose and treat BD. Importantly, we trained machine learning algorithms on our datasets that predicted the lithium response of BD subtypes with minimal errors, even when used on a different cohort of 24 BD patients acquired by a different laboratory. This proves the scalability of our methodology for predicting lithium response in BD and for a prompt and suitable decision on therapeutic interventions.
Original language | English |
---|---|
Pages (from-to) | 4280-4293 |
Number of pages | 14 |
Journal | Molecular Psychiatry |
Volume | 28 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2023 |
Bibliographical note
Publisher Copyright:© 2023, The Author(s).
ASJC Scopus subject areas
- Molecular Biology
- Cellular and Molecular Neuroscience
- Psychiatry and Mental health